Shares of South Korea’s drugmakers drop after Trump unveils tariffs

SK Biopharmaceuticals Co

26/09/2025 02:30

SEOUL, Sept 26 (Reuters) - Shares of South Korean drugmakers fell on Friday after U.S. President Donald Trump threatened new drug tariffs, with Samsung Biologics 207940.KS down 1.6%, off a more than eight-month low, while SK Biopharmaceuticals 326030.KS slid 2.6%.

Celltrion 068270.KS, which said on Tuesday it had paid $330 million to acquire Imclone Systems LLC from Eli Lilly LLY.N in the United States, rose 1.3% after recouping losses.

Trump threatened 100% duties on all imports of branded drugs from October 1, unless their makers had already broken ground for manufacturing plants in the United States.

 (Reporting by Jihoon Lee and Heekyong Yang; Editing by Clarence Fernandez)

 ((Heekyong.Yang@thomsonreuters.com;))